Evidence map›Paper›PMID 38980476›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US.

Tabea Tracksdorf, D Max Smith, Skyler Pearse, Emily J Cicali, Christina L Aquilante, Stuart A Scott, Teresa T Ho, Jai N Patel, J Kevin Hicks, Daniel L Hertz

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tabea TracksdorfDeparment of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St, Room 2560C, Ann Arbor, MI, 48109-1065, USA.
D Max SmithDepartment of Oncology, Georgetown University Medical Center, Washington, DC, USA.ORCID http://orcid.org/0000-0003-3667-2936
Skyler PearseHealth Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Emily J CicaliDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-3595-9321
Christina L AquilanteDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.ORCID http://orcid.org/0000-0001-6609-6920
Stuart A ScottDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5720-1864
Teresa T HoDepartment of Pathology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-2489-3099
Jai N PatelDepartment of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.ORCID http://orcid.org/0000-0001-9845-3697
J Kevin HicksDepartment of Pathology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-2314-0164
Daniel L HertzDeparment of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St, Room 2560C, Ann Arbor, MI, 48109-1065, USA. DLHertz@med.umich.edu.ORCID http://orcid.org/0000-0003-0501-1035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment DPYD testing is standard of care in many countries, but not the United States (US). This survey assessed pre-treatment DPYD testing approaches in the US to identify best practices for broader adoption.

methodsFrom August to October 2023, a 22-item Qualtrics

resultsResponses from 24 unique US sites that have implemented pre-treatment DPYD testing or have a detailed implementation plan in place were analyzed. Only 33% of sites ordered DPYD testing for all FP-treated patients; at the remaining sites, patients were tested depending on disease characteristics or clinician preference. Almost 50% of sites depend on individual clinicians to remember to order testing without the assistance of electronic alerts or workflow reminders. DPYD testing was most often conducted by commercial laboratories that tested for at least the four or five DPYD variants considered clinically actionable. Approximately 90% of sites reported receiving results within 10 days of ordering.

conclusionImplementing DPYD testing into routine clinical practice is feasible and requires a coordinated effort among the healthcare team. These results will be used to develop best practices for the clinical adoption of DPYD testing to prevent severe and fatal toxicity in cancer patients receiving FP chemotherapy.

Indexed as

Dihydropyrimidine Dehydrogenase DeficiencyDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticFluorouracilHumansNeoplasmsSurveys and QuestionnairesUnited StatesAntimetabolites, AntineoplasticDihydrouracil Dehydrogenase (NADP)FluorouracilClinical implementationDPYDFluoropyrimidinesOncologyPharmacogeneticsSurvey

Identifiers

PMID38980476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.